Intracranial tumors secondary to radiotherapy are rare. In this group gliomas are the rarest. Only 6 cases of glioblastoma multiforme (GBM) have been reported in patients undergoing radiotherapy (RT) for craniopharyngiomas of which only 4 have been in children less than 18 years of age. In recent years RT has become a mainstay of adjuvant therapy for recurrent or partially excised craniopharyngiomas. We report a child of 12 years who had previously undergone RT for a suprasellar craniopharyngioma and presented 10 years later with a GBM. This is the 5th pediatric case in literature demonstrating a GBM after RT for a craniopharyngioma. The implications of subjecting the pediatric population to RT for a benign lesion versus the outcome of gross total removal and management of RT induced tumors is discussed and the need to avail of safer alternatives such as stereotactic radiosurgery is stressed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928352PMC
http://dx.doi.org/10.3340/jkns.2014.55.1.54DOI Listing

Publication Analysis

Top Keywords

adjuvant radiotherapy
4
radiotherapy recommended
4
recommended pediatric
4
pediatric craniopharyngiomas?
4
craniopharyngiomas? intracranial
4
intracranial tumors
4
tumors secondary
4
secondary radiotherapy
4
radiotherapy rare
4
rare group
4

Similar Publications

Introduction And Importance: Chordoma is an uncommon malignant tumor that originates from the remnants of the primitive notochord in the embryo. They account for 1 % of intracranial tumors and 4 % of primary bone tumors. It is a locally aggressive tumor with a low risk of metastasis.

View Article and Find Full Text PDF

Introduction: Diffuse intrinsic pontine glioma (DIPG) in children comprises 80% of brainstem gliomas. In 2021, 5th edition of WHO CNS tumor classification defined H3K27M altered diffuse midline gliomas (DMGs) which replaced this entity. Lesion location precludes resection and the only current option available is radiotherapy.

View Article and Find Full Text PDF

Background: Oral cancer, particularly mucoepidermoid carcinoma (MEC), presents diagnostic challenges due to its histological diversity and rarity. This study aimed to develop machine learning (ML) models to predict survival outcomes for MEC patients and pioneer a clinically accessible prognostic tool.

Methods: Using the SEER database (2000-2020), we constructed predictive models with five ML algorithms: Random Forest Classifier (RFC), Gradient Boosting Classifier (GBC), Logistic Regression (LR), K-Nearest Neighbors (KNN), and Multilayer Perceptron (MLP).

View Article and Find Full Text PDF

Towards Effective Treatment of Glioblastoma: The Role of Combination Therapies and the Potential of Phytotherapy and Micotherapy.

Curr Issues Mol Biol

December 2024

Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Via Ferrata 9, 27100 Pavia, Italy.

Glioblastoma multiforme (GBM) is one of the most aggressive and difficult-to-treat brain tumors, with a poor prognosis due to its high resistance to conventional therapies. Current treatment options, including surgical resection, radiotherapy, and chemotherapy, have limited effectiveness in improving long-term survival. Despite the emergence of new therapies, monotherapy approaches have not shown significant improvements, highlighting the need for innovative therapeutic strategies.

View Article and Find Full Text PDF

Treatment of metastatic carotid body paraganglioma in a young female.

J Surg Case Rep

January 2025

Division of Vascular Surgery, Department of Surgery, Arrowhead Regional Medical Center, 400 N Pepper Ave, Colton, CA 92324, United States.

Carotid body tumors (CBTs) are rare head and neck paragangliomas that arise from the carotid body chemoreceptor at the common carotid bifurcation. These neoplasms are generally benign, slow-growing, nonsecreting, and well-vascularized. Metastasis occurs in ~5% of cases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!